Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CAZ/AVI

Phase 3Small molecule

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

CAZ/AVI is one of 14 small molecule programs targeting Outcome. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

13

Competitors

Pipeline

Status by Indication[3][1]

Indication

OutcomeRecruiting

OutcomePhase 3

Recruiting

Competition

Competitive Landscape

20 competitors in Outcome

#DrugCompanyPhaseTrials

Victoza

Promacta

Vafseo

AAkebia Therapeutics

Keytruda

Ozempic

T89

TTasly Pharmaceuticals, Inc.

CAZ/AVI

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Estrasorb

Amidate

Savaysa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Outcome1 trial

Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT06528028·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CAZ/AVI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAZ/AVI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAZ/AVI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Related News